Posts

Medtech Branding Begins With the Define Phase

Knutton described Alluvia Studio’s brand process as “define, refine, shine,” with the most important work happening at the beginning. The define phase is where a company does the harder, less visible work of understanding who it is, who it serves, what it stands for, and why the market should care. Burke said that for startups, this early definition is especially important because it directly affects how investors understand the company. “For any startup, I think the define phase is the most important thing that you can do and spend time on because it’s who you are and what value you’re bringing and why an investor should care,” Burke said. For more information visit here: https://www.slideshare.net/slideshow/medtech-branding-begins-with-the-define-phase/288275863

Medtech Branding: Why Startups Need to Define Their Story Early

At LSI USA ’26, the panel “If You Don’t Create Your Brand, Your Market (or Competitors) Will” explored a critical but often underprioritized part of company building: medtech branding. For early-stage innovators, brand is not simply a logo, color palette, or polished pitch deck. It is the foundation for how a company defines its purpose, positions its technology, earns credibility, and creates consistency with customers, investors, employees, and strategic partners. Moderated by Rachel Knutton, CEO of Alluvia Studio, the discussion featured Amanda DePalma, SVP of Ultrasound Global Marketing at Siemens Healthineers, and Terri Burke, Senior Partner at Intuitive Ventures. Together, they made a clear case for why brand development should begin long before a company is ready for commercial launch. Brand Starts Before the Logo For Burke, one of the most important misconceptions to correct is that brand begins with visual identity. “For me, a brand is a lot more than a logo or colors,” Burke...

Opening Fireside Chat: How Deep Tech is Reshaping a More Human Future of Healthcare | LSI USA '26

Join industry leaders as they discuss the transformative role of deep technology in creating a more human-centered healthcare system, highlighting innovative strategies and insights for the future. For more details watch this video: https://www.lifesciencemarketresearch.com/videos/opening-fireside-chat-how-deep  

Keynote: Bret Snyder CEO of W. L. Gore & Associates, and Lisa Carmel, Chair of Business Development, Mayo Clinic | LSI USA '26

Gain insights from industry leaders as they discuss innovative strategies for advancing healthcare and business development, highlighting the collaboration between Mayo Clinic and W. L. Gore & Associates. For more details watch this video: https://www.lifesciencemarketresearch.com/videos/keynote-bret-snyder-ceo-of

Keynote: Mike Mahoney, CEO of Boston Scientific, and Peter Noseworthy, Mayo Clinic | LSI USA '26

Keynote: Mike Mahoney, CEO of Boston Scientific, and Peter Noseworthy, Chair, Cardiac Electrophysiology, Professor, Medical Director at Mayo Clinic | LSI USA ’26. Join industry leaders as they discuss innovations and strategies in cardiac care, focusing on the intersection of medical technology and clinical practice. For more details watch this video: https://www.lifesciencemarketresearch.com/videos/keynote-mike-mahoney-ceo-of

Opening Fireside Chat with Omar Ishrak and Jean Nehme | LSI USA '26

Opening Fireside Chat with Omar Ishrak and Jean Nehme | LSI USA ’26. Join industry leaders as they discuss the future of healthcare innovation, drawing on insights from leadership experiences at Medtronic and Qubit Health Capital. For more details watch this video: https://www.lifesciencemarketresearch.com/videos/opening-fireside-chat-with-omar

Device-Based Therapy for Hypertension: New Frontiers in Patient Care

“If you think about hypertension, it’s a global healthcare crisis,” said Eso. “Half of this auditorium probably has it. It’s bigger than diabetes, bigger than many other diseases from a cardiovascular perspective.” Eso traced Medtronic’s entry into hypertension therapeutics back to its 2009 investment in Ardian, the pioneer behind renal denervation devices. At the time, hypertension management was still viewed almost exclusively through a pharmaceutical lens. Devices weren’t yet considered part of the solution. However, early clinical learnings revealed significant gaps that medication alone couldn’t fill — particularly in adherence. To read more about visit here: https://anyflip.com/ybicl/xonm/basic